CNTA — Centessa Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $1.84bn
- $1.46bn
- 30
- 17
- 52
- 24
Annual income statement for Centessa Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 6.85 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 10.1 | 374 | 212 | 178 | 235 |
| Operating Profit | -10.1 | -374 | -212 | -171 | -235 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.7 | -381 | -217 | -176 | -233 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.7 | -381 | -216 | -151 | -236 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.7 | -381 | -216 | -151 | -236 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.7 | -381 | -216 | -151 | -236 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.126 | -2.14 | -2.31 | -1.57 | -1.87 |